Osimertinib (mesylate) (Standard)

Osimertinib (mesylate) (Standard)

• CAS Number: 1421373-66-1
• UNSPSC Description: Osimertinib (mesylate) (Standard) is the analytical standard of Osimertinib (mesylate). This product is intended for research and analytical applications. Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
• Target Antigen: EGFR
• Type: Reference Standards
• Related Pathways: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/osimertinib-mesylate-standard.html
• Smiles: C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
• Molecular Weight: 595.71
• References & Citations: [1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.|[2][2]Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750.
• Shipping Conditions: Room Temperature